07:00 , Oct 21, 2013 |  BC Week In Review  |  Company News

Aqualis management update

Aqualis ASA (OSE:AQUA), Oslo, Norway   Business: Drug delivery, Cancer, Infectious   Transitioned: Ole Eriksen to healthcare CBO from COO  ...
07:00 , Sep 16, 2013 |  BC Week In Review  |  Company News

Clavis, Aqualis Offshore deal

Clavis signed a letter of intent to acquire engineering and marine consultancy firm Aqualis in a NOK70 million ($11.5 million) stock deal. Clavis said the deal represents a change in strategic direction, but its existing...
07:00 , Sep 9, 2013 |  BC Week In Review  |  Financial News

Clavis proposes rights offering of units

Clavis Pharma ASA (OSE: CLAVIS), Oslo, Norway   Business: Drug delivery, Cancer, Infectious   Date announced: 9/4/13   Type: Rights offering of units   To be raised: Up to NOK54 million ($8.8 million)   Price...
07:00 , Jul 11, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Chronic myelogenous leukemia (CML) MAP kinase interacting serine-threonine kinase 1 (MKNK1; MNK1); MKNK2 (MNK2); eukaryotic translation initiation factor 4E (eIF4E) In vitro and mouse studies...
07:00 , Jul 1, 2013 |  BioCentury  |  Finance

2Q Stock Wrap-Up: If it ain't broke

Despite one segment that finished the second quarter in the red, all market cap groups are still up for the year. In 2Q13, the sector was led by large caps, which closed up 4%, marking...
07:00 , Jun 10, 2013 |  BioCentury  |  Finance

Finding a 4-leaf clover

After presenting early Phase I data at ASCO, Clovis Oncology Inc. (NASDAQ:CLVS) got back more than four times the market cap it lost late last year when lead program CO-101 failed a pivotal Phase II...
07:00 , May 27, 2013 |  BC Week In Review  |  Company News

Clavis board of directors update

Clavis Pharma ASA (OSE:CLAVIS), Oslo, Norway   Business: Drug delivery, Cancer, Infectious   Transitioned: Martin Nes, a director, to interim chairman; he replaces Anders Wiklund, who resigned  ...
07:00 , May 27, 2013 |  BC Week In Review  |  Company News

Clavis management update

Clavis Pharma ASA (OSE:CLAVIS), Oslo, Norway   Business: Drug delivery, Cancer, Infectious   Transitioned: Gunnar Manum to acting CEO while remaining CFO  ...
07:00 , May 27, 2013 |  BioCentury  |  Finance

Demand disequilibrium

BioCentury's 11th annual European Iceberg survey sees funding demand continue to fall for a shrinking number of public clinical-stage biotechs in Europe, while the capital demanded by the growing cadre of venture biotechs continues to...
07:00 , May 20, 2013 |  BC Week In Review  |  Company News

Clavis cancer news

Clavis said it is undergoing a "significant down scaling" of its operations following the discontinued development of elacytarabine to treat acute myelogenous leukemia in April. Clavis said most of the employees will leave the company...